On 14 November 2024, GlaxoSmithKline (GSK) announced positive results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep® (belantamab mafodotin) in combination with BorDex (bortezomib plus dexamethasone) as a second-line or later treatment for relapsed or refractory multiple myeloma (RRMM). The results demonstrated that the Blenrep® combination treatment significantly reduced the risk of death versus standard of care daratumumab plus BorDex. GSK plans to present the full results at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition on 9 December 2024.
Earlier interim data from the DREAMM-7 trial was reported in February 2024, showing a 59% further reduction in risk of disease progression or death, 23.2 more months of median progression-free survival, and a 43% reduction in risk of death.
This follows GSK’s announcement in September 2024 that Japan’s Ministry of Health accepted for review a new drug application for Blenrep® in combination with BorDex or PomDex (pomalidomide plus dexamethasone) as a treatment for RRMM.